Mouse GLA / Alpha-galactosidase A Protein (His Tag)

Produkt-Information von GLA / Alpha-galactosidase A Protein

QC Testing von GLA / Alpha-galactosidase A Protein

Purity	>95% as determined by SDS-PAGE	SDS-PAGE: GLA / Alpha-galactosidase A protein
Endotoxin	< 1.0 EU per μg of the protein as determined by the LAL method
Stability	Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N terminal	Leu 34
Molecular Mass	The recombinant mouse Gla comprises 399 amino acids and has a predicted molecular mass of 45.6 kDa. The apparent molecular mass of the protein is approximately 46-52 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Formulation	Lyophilized from a 0.2μm filtered solution of PBS, pH7.4. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.

Usage Guide von GLA / Alpha-galactosidase A Protein

Verwandte Produkte & Themen von GLA / Alpha-galactosidase A Protein

Enzyme>>Carbohydrate Metabolism Enzymes>>alpha-Galactosidase A/GLA

Beschreibung von GLA / Alpha-galactosidase A Protein

Alpha-galactosidase A, also known as Alpha-D-galactoside galactohydrolase, Alpha-D-galactosidase A, Melibiase and GLA, is a member of the glycosyl hydrolase 27 family. GLA is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease. Defects in GLA are the cause of Fabry disease (FD) which is a rare X-linked sphingolipidosis disease where glycolipid accumulates in many tissues. The disease consists of an inborn error of glycosphingolipid catabolism. FD patients show systemic accumulation of globotriaoslyceramide (Gb3) and related glycosphingolipids in the plasma and cellular lysosomes throughout the body. Clinical recognition in males results from characteristic skin lesions (angiokeratomas) over the lower trunk. Patients may show ocular deposits, febrile episodes, and burning pain in the extremities. Death results from renal failure, cardiac or cerebral complications of hypertension or other vascular disease. Deficiency of GLA leads to the accumulation of glycosphingolipids in the vasculature leading to multiorgan pathology. In addition to well-described microvascular disease, deficiency of GLA is also characterized by premature macrovascular events such as stroke and possibly myocardial infarction.

References

1. Koide T. et al., 1990, FEBS Lett. 259: 353-6.
2. Yang C-C. et al., 2003, Clin. Genet. 63: 205-9.
3. Verovnik F. et al., 2004, Eur J Hum Genet. 12: 678-81.
4. Nance CS. et al., 2006, Arch Neurol. 63: 453-7.

Sino Biological Inc. liefert Mouse GLA / Alpha-galactosidase A Protein (His Tag) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über Mouse GLA / Alpha-galactosidase A Protein (His Tag) lesen Sie bitte: http://www.sinobiological.com/GLA-Alpha-galactosidase-A-Protein-g-9142.html